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Abstract
Background: The C677T variant in the methylenetetrahydrofolate reductase (MTHFR) gene is
associated with increased levels of circulating homocysteine and is a mild risk factor for vascular
disease. Migraine, with and without aura (MA and MO), is a prevalent and complex neurovascular
disorder that may also be affected by genetically influenced hyperhomocysteinaemia. To determine
whether the C677T variant in the MTHFR gene is associated with migraine susceptibility we utilised
unrelated and family-based case-control study designs.
Methods: A total of 652 Caucasian migraine cases were investigated in this study. The MTHFR
C677T variant was genotyped in 270 unrelated migraine cases and 270 controls as well as 382
affected subjects from 92 multiplex pedigrees.
Results: In the unrelated case-control sample we observed an over-representation of the 677T
allele in migraine patients compared to controls, specifically for the MA subtype (40% vs. 33%) (χ2
= 5.70, P = 0.017). The Armitage test for trend indicated a significant dosage effect of the risk allele
(T) for MA (χ2 = 5.72, P = 0.017). This linear trend was also present in the independent family-based
sample (χ2 = 4.25, Padjusted = 0.039). Overall, our results indicate that the T/T genotype confers a
modest, yet significant, increase in risk for the MA subtype (odds ratio: 2.0 – 2.5). No increased
risk for the MO subtype was observed (P > 0.05).
Conclusions: In Caucasians, the C677T variant in the MTHFR gene influences susceptibility to
MA, but not MO. Investigation into the enzyme activity of MTHFR and the role of homocysteine
in the pathophysiology of migraine is warranted.
Background
Migraine is a debilitating neurovascular disease that
affects approximately 12% of the Caucasian population. It
is characterised by nausea and vomiting, photophobia
and phonophobia, neurological disturbances and severe
recurrent headache. Pharmaceutical treatments for
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migraine exhibit variable efficacy among patients and
there is no laboratory-based diagnostic test available. At
present, migraine is clinically diagnosed based on criteria
specified by the International Headache Society (IHS).
The IHS has defined two major classes of migraine. These
are migraine without aura (MO), which accounts for
~70% of all migraine in the population, and migraine
with aura (MA), which comprises ~25% of all migraine
[1]. The two subtypes have substantial symptomatic over-
lap, but MA sufferers experience distinguishing neurolog-
ical disturbances (the aura) that usually precede the
headache phase of an attack [1].
Strong familial aggregation of migraine indicates a signif-
icant genetic component for the disease [2]. Heritability is
estimated to be between 40% and 60%, indicating that
the disease is partly explained by non-genetic determi-
nants [3,4]. Thus, migraine is a multifactorial (complex)
disease of which the genetic aetiology is likely to be com-
prised of a number of modest effect susceptibility genes
that perhaps act in combination. It is likely that both
migraine subtypes (MO and MA) have some genetic deter-
minants in common although different modifying factors
(including genetic and lifestyle triggers) may contribute to
the variable expression of the clinical end-point.
The pathophysiology of migraine is not completely
understood and continues to be rigorously investigated.
For MA, a dramatic reduction in cerebral blood flow is
associated with the depolarisation wave that propagates
across the brain cortex (cortical spreading depression;
CSD) [5]. The characteristic head pain that is common to
both MA and MO may arise due to dilation of cerebral
blood vessels following activation of the trigeminovascu-
lar system (TVS). The CSD can activate the TVS, providing
a possible link between migraine aura and headache [6].
Therefore, biochemical factors that have the potential to
disrupt vascular endothelial function and cerebral blood
flow, leading to CSD and/or affecting the TVS, are impor-
tant targets for involvement in migraine susceptibility [7].
Homocysteine, a highly reactive amino acid, has been
shown to produce endothelial cell injury in both experi-
mental animal and cell culture studies [8,9]. The patho-
physiological consequences of such homocysteine-related
endothelial injury may include impaired release of nitric
oxide (NO) [10]. In turn, altered bioavailability of NO
may cause abnormal reactions between the vessel wall,
platelets, and macrophages [11] leading to significant
alterations in vascular function and the coagulant proper-
ties of the blood [12,13]. Thus, it is within reason that
homocysteine-related endothelial dysfunction may be
involved in the initiation and maintenance of a migraine
episode. In support of this, studies have also demon-
strated that the firing rate of trigeminal neurons respond-
ing to pain increases with the application of D, L-
homocysteic acid, a substance that mimics the effect of
homocysteine, [14,15]. In humans, homocysteine is
metabolised by methylenetetrahydofolate reductase
(MTHFR). This enzyme catalyses the reduction of 5,10-
methylenetetrahydofolate to 5-methylenetetrahydofolate,
which is the circulatory form of folate and carbon donor
for re-methylation of homocysteine to methionine [16].
The human MTHFR gene has been localised to chromo-
some 1p36 and consists of 11 exons spanning ~17 kb
[17]. A common MTHFR gene variant (C677T) alters the
amino acid sequence, substituting alanine (Ala) for valine
(Val) at position 222. Individuals with the Val residue
may exhibit significantly reduced MTHFR enzyme activity
whereby, compared to baseline levels, the mean activity is
65% in the Ala/Val heterozygote and 30% in the Val/Val
homozygous state [16]. The latter enzymatic form can
lead to mild elevation in plasma homocysteine levels par-
ticularly if dietary folate intake is low [16,18]. Mild hyper-
homocysteinaemia is known to increase risk of
cardiovascular disease (CVD) including coronary, cere-
bral, and peripheral vascular disease [16,18,19]. More
specifically, meta-analyses have concluded that the
homozygous TT genotype of the MTHFR gene variant
(C677T) is a modest, yet significant, genetic risk factor for
ischaemic stroke, another severe neurovascular disease
(odds ratio (OR): 1.5 – 2) [18,20]. Interestingly, the
migraine disorder itself is also associated with an
increased risk of ischaemic stroke, particularly with MA
[21-25]. Indeed, the CSD, which is characteristic of MA, as
well as changes in cerebral blood flow and headache, can
also occur during a stroke episode [26]. Based on the
comorbidity of migraine and stroke and the role homo-
cysteine seems to play in disturbing in the cerebrocircula-
tory system, it is possible that the MTHFR C677T variant
may represent an important genetic determinant for the
vascular pathophysiologies underlying both neurovascu-
lar conditions. The objective of our study was to deter-
mine whether the MTHFR C677T variant is associated
with migraine susceptibility in Caucasians utilising unre-
lated and family-based case-control designs.
Methods
Disease diagnosis
Our study protocol was approved by the Griffith Univer-
sity Ethics Committee for Experimentation on Humans
and all subjects gave informed consent. Migraine patients
were shown to exhibit phenotypic variation, which
included differences in age of onset, frequency and sever-
ity of attacks, environmental triggers and medication
response. However, all affected individuals were diag-
nosed as having either MA or MO by an experienced clin-
ical neurologist using the IHS criteria (MA = criteria 1.2.1
and MO = criteria 1.1) [1]. The small number of patients
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experiencing both subtypes of migraine was phenotyped
as being affected with MA. To reduce confounding, any
volunteer that reported being affected with known
migraine comorbid conditions such as mental illness (e.g.
depression) and CVD (e.g. stroke) were not included in
the study.
Study design and samples
To test for association of the MTHFR C677T variant to
migraine, we utilised a combination of traditional and
modern case-control study designs. In general, the case-
control approach remains a practical and powerful strat-
egy for detecting genetic variants that confer a modest
effect on disease susceptibility provided its shortcomings
are addressed appropriately [27,28]. For this study we ini-
tially implemented the popular unrelated case-control
approach to compare genotype and allele frequencies.
This was followed by family-based case-control tests for
association utilising a) a transmission disequilibrium-
type test (TDT-type) in nuclear pedigrees [29] and b) a sta-
tistical method for comparing related cases to unrelated
controls [30]. The difference between this latter design
and the traditional unrelated case-control design is that,
provided relatedness is accounted for, multiple cases from
a single affected family(s) can be included in the analysis.
This can result in substantial information gain over the
use of family-based controls [30].
The unrelated case-control panel examined in this study is
a clinic-based sample comprised of 270 unrelated migraine
cases and a matched group of 270 unrelated non-migraine
controls. Of this unrelated case group, 68% were female,
63% were phenotyped with MA, and 90% of patients had
a known family history of migraine or at least one affected
first degree relative. The unrelated control group was care-
fully matched with the case group for the variables; age (±
5 years), gender and ethnicity (Caucasian and of British
descent). The control group was recruited from the same
geographical location as the affected group (east coast of
Australia). We also utilised an independent family-based
sample comprised of 92 affected pedigrees. Of the 432
subjects in this pedigree sample, 290 (67%) were female,
382 (88%) were diagnosed with migraine (MA and/or
MO) and 295 (68%) were affected with MA. Overall, our
study included a total of 652 migraine cases, of which 465
(71%) suffered from MA.
Genotyping
Genomic DNA was isolated from whole blood by a stand-
ard salting out procedure. DNA fragments containing the
C677T MTHFR variant were amplified by PCR using the
oligonucleotides published by Kowa et al. (2000) [31].
The sense primer sequence was 5'-TGA AGG AGA AGG
TGT CTG CGG GA-3', and the antisense sequence was 5'-
AGG ACG GTG CGG TGA GAG TG-3'. PCR conditions
were as follows; 1.75 mM of MgCl2, 1 × standard PCR
buffer, 0.2 mM of dNTPs, 0.2 µM each of forward and
reverse primers, 0.16 g/l of BSA, 1 unit of Taq polymerase,
40 ng of genomic DNA, mixed to final volume of 25 µ l
with sterile distilled water. The thermal cycle parameters
included: 1 cycle at 95°C for 3 min for an initial denatur-
ation, followed by 35 cycles of denaturation for 1 min at
94°C, primer annealing for 1 min at 65°C, primer exten-
sion for 2 min at 72°C and a final extension for 10 min at
72°C [31]. This amplification reaction resulted in the syn-
thesis of a 198-bp fragment.
The C to T substitution at nucleotide 677 in the MTHFR
gene introduces a restriction site for the HinfI enzyme.
This enzyme was used to distinguish the alleles by cleav-
ing the mutant fragment into 175-bp and 23-bp frag-
ments. For the digestion reaction, 7 units of HinfI, 2 µl of
NE buffer II and 2.3 µl of sterile water were added to each
PCR product mix for a final volume of 20 µl. Samples
were digested overnight at 37°C and then fractionated by
using a 5% ultra-high-resolution agarose gel, stained with
ethidium bromide and visualised under ultraviolet light.
To confirm results, the DNA samples were also genotyped
using an ABI-310 Genetic Analyser, which is capable of
distinguishing DNA fragments that differ by as little as 2
bp. For this technique, the reverse PCR primer was
labelled with 5-carboxyfluorescein (FAM) fluorescent dye.
Following initial PCR and restriction fragment length pol-
ymorphism digest, 1 µl of each digested PCR product was
added to 12 µl of formaldehyde/size standard mix (Per-
kin-Elmer). This mixture was denatured for 2 minutes at
95°C before running on the ABI-310 Genetic Analyser.
An independent laboratory technician, blinded to the ini-
tial genotyping processing, performed quality control
checks for the MTHFR gene variant by repeating the PCR
and genotyping of a random selection of 100 subjects. All
genotype discrepancies were rectified or excluded from
subsequent data analysis.
Statistical data analysis
Unrelated case-control association analyses
Genotype and allele frequencies for the MTHFR C677T
variant were calculated from observed genotype counts.
As a statistical control for systematic genotyping error and
population stratification, the expected genotype propor-
tions according to the Hardy-Weinberg law were calcu-
lated and compared to observed genotypes. Genotype and
allele frequencies were initially assessed for association
with migraine using conventional contingency table anal-
yses incorporating the standard chi-squared test for inde-
pendence. This analysis produces a χ2 statistic with one or
two degrees of freedom and corresponding P-values for
allele and genotype distributions, respectively. To assess
the dosage effect of possessing zero, one or two copies of
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the risk allele (T) (i.e. an additive effect), the Armitage test
for linear trend in proportions was performed on the gen-
otype frequency data. Genetic risk magnitudes (effect size)
were estimated by calculating ORs with 95% confidence
intervals.
Family-based association analyses
Our study of the MTHFR C677T variant also involved
family-based association analyses of 92 migraine pedi-
grees. Mendelian inheritance of the MTHFR alleles in ped-
igrees was checked using the PEDMANAGER program.
The Family Based Association Test (FBAT) was performed
on the pedigree data using the software package of Laird et
al. (2000) [29]. This is a transmission disequilibrium test
(TDT) type approach for assessing association between
DNA variant alleles and disease phenotype under the
standard genetic models (dominant, recessive and addi-
tive). Unlike the classic TDT, which was designed for spe-
cific pedigree structures (ie. parent-child triads), the FBAT
can appropriately utilise data from multiple nuclear fam-
ilies derived from a single multiplex pedigree to test for
association [29].
We also utilised a powerful statistical test developed by
Slager and Schaid (2001) [30], which involves comparing
genotype frequencies of genetically related cases (sampled
from multiplex affected families) with the unrelated con-
trol group frequencies. This method is based on the Armit-
age test for trend and includes a variance estimate that
appropriately accounts for the non-independence of
related cases. Thus, this method allows assessment of the
dosage effect conferred by the risk allele whilst maintain-
ing the correct type I error rate [30]. For this analysis we
used the GENEHUNTER program to estimate the IBD-
sharing probabilities [32] and the S-PLUS function of
Slager and Schaid (2001) [30] to calculate the association
test statistics for the pedigree data. Unaffected family
members can be used as a comparative group and may
possibly reduce false positives arising from population
stratification. However, for our pedigree sample there was
only 50 individuals not diagnosed with migraine and
many of these individuals (n = 33) were labelled as phe-
notype "unknown". Therefore these familial controls were
considered inappropriate for comparison.
It is unclear to what extent the MA and MO subtypes are
influenced by the same genetic aetiologies. Therefore, we
performed stratified analyses of the migraine subtypes
(MO subtype and MA subtype), in addition to compari-
sons of all migraineurs grouped together (MO+MA). Anal-
ysis of the group of individuals with co-occurring MA and
MO was not conducted due to small numbers. The con-
ventional α-level of 0.05 was specified as the significance
threshold for all analyses performed. We chose not to cor-
rect for multiple comparisons but opted instead to estab-
lish the credibility of a positive association by verification
in an independent sample.
Results
Unrelated case-control analysis
Table 1 displays the frequency distributions observed for
the MTHFR C677T variant for the unrelated case and con-
trol groups. Genotype and allele frequencies were deter-
mined for 268 migraine patients and 269 controls. The
observed genotypes for the case and control groups did
not deviate significantly from Hardy-Weinberg expecta-
tions (P > 0.1). The genotype frequencies in the migraine
control group (43%, 48%, 9% for C/C, C/T and T/T,
respectively) are very similar to an independent control
group (n = 249) utilised for case-control studies of hyper-
tension conducted in our laboratory (42%, 48%, 10% for
C/C, C/T and T/T, respectively). Furthermore, the fre-
quency of the T allele in our control group (33%) is also
consistent with the proportion of this allele in the general
Caucasian population (34%) [18,33], giving us confi-
dence that the unrelated non-migraineurs used in this
study constitute a reliable (unbiased) comparative panel.
Contingency table analysis of the MTHFR C677T fre-
quency data indicated that the risk allele (T) was over-rep-
resented in the migraine group compared to the control
group (38% vs. 33%), although the P value for this com-
parison did not reach statistical significance (χ2 = 3.36, P
= 0.066). The proportion of the T allele in the MA sub-
Table 1: Distribution of MTHFR C677T (genotype and allele) frequencies in unrelated migraine and control groups.
Genotypes Alleles
Group C/C C/T T/T N (genotypes) C T
MO+MA 104 (39%) 125 (46%) 39 (15%) 268 333 (62%) 203 (38%)
MA* 64 (38%) 72 (43%) 32 (19%) 168 200 (60%) 136 (40%)
MO 40 (40%) 53 (53%) 7 (7%) 100 133 (66%) 67 (34%)
Control 117 (43%) 129 (48%) 23 (9%) 269 363 (67%) 175 (33%)
*genotype distribution comparison (Trend χ2 = 5.72, P = 0.017), T/T genotype vs. C/C (OR = 2.54, 95% CI: 1.37 – 4.71).
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group however, was shown to be significantly higher than
in the control group (40% vs. 33%) (χ2 = 5.70, P = 0.017).
Further comparison of the genotype data indicated a dif-
ference in frequency distributions, with the homozygous
T/T genotype being over-represented in the migraine
group (15% vs. 9%). Stratified analyses indicated that this
difference was specifically attributed to the MA subtype
group, with the T/T frequencies being significantly higher
in cases compared to controls (19% vs. 9%) (χ2 = 10.37, P
= 0.006). Interestingly, there was also a significant dosage
(additive) effect of the risk allele for MA as assessed by the
Armitage test for linearity (χ2 = 5.72, P = 0.017). To deter-
mine the magnitude of the increased risk of migraine con-
ferred specifically by the homozygous T/T genotype, odds
ratios were calculated after dichotomising the genotype
frequency data into risk "T/T" and baseline "C/C" geno-
type groups. Comparing the total migraine group against
controls under this grouping scheme produced an OR of
1.91 with a 95% CI of 1.07 – 3.04 (P = 0.027), and the MA
subtype comparison produced an OR of 2.54 (95% CI:
1.37 – 4.71, P = 0.0025). There was no association
detected for the C677T variant under a dominant group-
ing scheme. Furthermore, no genotypic association was
indicated for the MTHFR gene variant and the MO sub-
type (P > 0.1), nor was there any gender-specific associa-
tions observed for this variant (results not shown).
Family-based case-control analysis
In genetic association studies it is important to substanti-
ate positive findings in independent samples. Therefore,
we also genotyped the MTHFR C677T variant in an inde-
pendent sample of migraine pedigrees. The frequency of
the risk allele in the affected members of the pedigree
sample (0.39) was similar to that observed in the unre-
lated case group (0.38) and greater than that of the unre-
lated control group (0.33). Genotypes for the family-
based case groups (Table 2) conform to Hardy-Weinberg
equilibrium expectations (P > 0.05).
Our initial association analysis of the pedigree data
involved calculation of TDT-type statistics using the FBAT
program [29]. The program automatically decomposed
the 92 multiplex pedigrees into 174 nuclear families for
this analysis. Based on the results of the unrelated case-
control analysis we assessed the family data under both
additive and recessive inheritance models and considered
"MO+MA" and "MA subtype" as disease phenotypes.
Encouragingly, the results under both disease models sug-
gested an association, indicating over-transmission of the
677T allele from parents to migraine-affected offspring.
However, the TDT-type statistics produced were not sig-
nificant for either migraine phenotype tested (P > 0.10). It
is important to note that, due to the relatively low degree
of heterozygosity for this MTHFR gene variant (~0.48),
less than 30 of all 174 nuclear families examined had het-
erozygous parents that could provide allele transmission
information to affected offspring for this association anal-
ysis. That is, inheritance phase was indiscernible in many
families and therefore the power to detect the expected
association of the MTHFR C677T variant and migraine, as
detected in the unrelated case-control analysis, was
severely diminished. This FBAT result is not really surpris-
ing and exemplifies the substantial analytical inefficien-
cies that may occur when testing for association of a bi-
allelic variant by allele transmission from parental con-
trols [28,34].
To overcome this information loss we implemented a
simple statistical method that was designed to compare
genotype frequencies from family-based case groups
(sampled from multiple affected families) to frequencies
from unrelated control groups (as used in the unrelated
case control analyses). This statistical method correctly
adjusts for correlation of genotypes in the family data and
has been successfully utilised to implicate the luteinizing
hormone β gene in prostate cancer susceptibility [30].
Table 2 summarises the genotype data of the MTHFR
C677T variant obtained from all migraineurs in the sam-
ple of 92 migraine pedigrees. As observed from the geno-
type frequency distributions in the unrelated case group
(Table 1), the T/T genotype was over-represented in both
case groups from the family-based sample (MA+MO and
Table 2: Distribution of MTHFR C677T genotypes in family-based migraine case and unrelated control groups.
Genotypes Alleles
Group C/C C/T T/T N (genotypes) C T
Related-MO+MA 112 (35%) 167 (52%) 40 (13%) 319 391 (61%) 247 (39%)
Related MA* 84 (34%) 132 (53%) 31 (13%) 247 300 (61%) 194 (39%)
Unrelated Control 117 (43%) 129 (48%) 23 (9%) 269 363 (67%) 175 (33%)
*genotype distribution comparison (Trend χ2 = 4.25, P = 0.039 adjusted for relatedness in affecteds), T/T genotype vs C/C (OR = 1.88, 95% CI: 1.01 
– 3.52).
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MA subtype groups) compared to the unrelated control
group (13% vs. 9%). Ignoring the inherent non-inde-
pendence in the family-based case sample data, we
observed differences between the frequency distributions
of these groups that approached statistical significance (χ2
= 5.36, P = 0.069; χ2 = 5.71, P = 0.058, respectively). If
weights are assumed to be equal to the number of high-
risk alleles (i.e. there is a gene dosage effect) the unad-
justed Armitage trend statistic was significant for both
MO+MA and MA-subtype groups (χ2 = 5.36, P = 0.021
and χ2 = 5.67, P = 0.017). Importantly, this linear trend in
proportions remained significant for the MA-subtype after
adjusting for the relatedness in the case groups (χ2 = 4.25,
Padjusted = 0.039). Further risk assessment of the MA-sub-
type produced an OR of 1.88 (95% CI: 1.01 – 3.52) after
accounting for familial relationships.
Discussion
The multifactorial nature of the common forms of
migraine has so far prevented researchers from clearly
identifying the predisposing genetic mechanisms. The
investigation of candidate genes utilising case-control
association designs is a powerful and direct strategy for
detecting disease susceptibility genes of modest effect
[27,30]. To date there have been numerous such studies
reporting positive associations of candidate gene variants
and migraine. Notably, polymorphisms within the
dopamine 2 receptor (DRD2), dopamine beta-hydroxy-
lase (DBH), and recently, insulin receptor (INSR) genes
have been implicated in migraine susceptibility [35-37].
These genes are not only physiologically plausible candi-
dates, but importantly, the specific associations have been
verified in independent migraine samples. Despite this,
the functional significance of these susceptibility gene var-
iants and the role they play in migraine pathophysiology
is yet to be determined.
In addition to disturbances in neurological pathways,
migraine pathophysiology is partly explained by changes
in vascular tension and altered cerebral blood flow [5,6].
Indeed, it is possible that vascular disturbances may act as
a trigger for downstream neurological manifestations.
Hence, molecular mechanisms that have the potential to
affect vascular endothelial function should be targeted for
involvement in migraine susceptibility. An elevation in
circulatory homocysteine levels is thought to disrupt
endothelial cells and alter the coagulant properties of the
blood [13]. Interestingly, a recent meta-analysis indicated
that mild hyperhomocysteinemia may by a "causal" risk
factor for cerebro- and cardio-vascular disease and sug-
gested that lowering homocysteine levels by simple die-
tary folate supplementation may reduce CVD risk [18].
Experiments on animal models suggest that hyperhomo-
cysteinemia may also increase susceptibility to migraine
by heightening cerebral artery sensitivity [15]. In addition,
elevated levels of homocysteine have been reported in
patients affected with MA [38]. It has been shown that the
677T allele in the MTHFR gene is directly correlated with
decreased enzymatic activity and the T/T genotype is indi-
rectly associated with mild hyperhomocysteinaemia pos-
sibly leading to vascular disease [16,18].
The objective of our study was to determine the preva-
lence of the MTHFR allele (677T) in Caucasian
migraineurs and to test for a relationship of this variant to
migraine susceptibility using unrelated case-control and
family-based association designs. Statistical analyses of
the unrelated case-control data revealed that the C677T
variant was associated with migraine. Stratification by
migraine subtype indicated that this association was not
arising in the MO case group but attributed specifically to
MA. Analysis of both the unrelated and family-based case
groups indicated a linear trend in the proportion of MA
cases as the number of risk alleles increased, suggesting a
gene dosage (additive) effect. This trend is consistent with
observed correlations in MTHFR enzyme activity accord-
ing to the number of copies of the Val residue correspond-
ing to the 677T allele [16]. For both migraine case groups
we also observed a significant over-representation of the
T/T genotype in the migraineurs compared to controls,
indicating the odds of being affected with MA (the effect
size) to be approximately 2 – 2.5 times greater in those
homozygous for the T allele compared with C/C
homozygotes.
We are not the first researchers to have investigated the
MTHFR C677T variant in relation to migraine susceptibil-
ity. A genetic association study by Kowa et al. (2000) [31],
originally reported a positive association between the
MTHFR C677T variant and migraine in a Japanese case-
control cohort. These researchers indicated an increased
risk of migraine (ie. MA+MO) in Japanese individuals
possessing the homozygous T/T genotype. Stratified anal-
yses specifically showed that the T/T genotype was signif-
icantly over-represented in these Japanese patients with
MA compared to non-migraine controls (40% vs. 9.6%),
producing an OR of ~6 [31]. These positive findings were
reinforced by another recent migraine case-control study
conducted in a Turkish population [40]. These researchers
reported that the MTHFR C677T is associated with
migraine and also indicated that the T/T genotype specifi-
cally increased risk of MA (OR ~10). It is important to
note that the frequency of the MTHFR 677T allele, and
indeed migraine prevalence, is known to vary substan-
tially among different ethnic populations [33,39]. Thus,
although our association study nicely supports the find-
ings of both Kowa et al. (2000) [31] and Kara et al. (2003)
[40], it cannot be considered a true replication of associa-
tion. The differing ethnic backgrounds of the research sub-
jects in the two previous studies may also partially explain
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the much larger ORs reported compared to the more mod-
est effect seen in the Caucasians of British descent that we
investigated. Nevertheless, all three migraine association
studies of the C677T variant show a similar overall trend,
and interpreted together, provide compelling evidence
that the homozygous T/T genotype of the MTHFR gene,
perhaps leading to reduced MTHFR enzyme activity and
mild hyperhomocysteinemia, increases susceptibility to
migraine, particularly MA.
There is convincing epidemiological evidence indicating
an association between migraine and stroke [23,24].
Although it is not conclusive, studies have indicated that
this relationship may be specific to MA [26,41]. Interest-
ingly, the CSD, which is characteristic of MA, as well as
changes in cerebral blood flow and headache, can also
occur during stroke [26]. It is possible that higher than
normal levels of homocysteine may lead to temporary cer-
ebral thrombosis and/or altered blood flow allowing less
oxygen into the brain and manifesting the symptoms
common to MA and ischaemic stroke [40]. Whilst our
study was not designed to investigate the comorbidity of
migraine and stroke, our findings lead us to suspect that
the C677T variant in the MTHFR gene may represent a
non-coincidental risk factor for both diseases. If this were
true, certain genes identified as stroke risk factors, such as
those with the potential to cause cerebral vascular dam-
age, blood coagulation and flow alteration, should also be
considered candidates for future studies into the molecu-
lar genetics of migraine.
Conclusion
Our study confirmed an association between the MTHFR
C667T mutation and migraine susceptibility, specifically
indicating the T/T genotype to be a modest risk factor for
migraine with aura, but not migraine without aura, in
Caucasians. Appropriately designed studies are now nec-
essary to determine the impact of this MTHFR gene vari-
ant on homocysteine levels in migraineurs. Finally,
dietary folate supplementation, as a modifier of homo-
cysteine levels, should be investigated as a simple thera-
peutic option (a nutraceutical) for the long-term
treatment of migraine.
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